Mode
Text Size
Log in / Sign up

Baseline vitamin D deficiency occurred in 73.08% of TAO patients receiving IVGC therapy with calcium supplementationSimple Blood Test Could Predict Thyroid Eye Treatment Success

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that baseline 25(OH)D deficiency was present in 73.08% of TAO patients receiving IVGC therapy.

This retrospective cohort study included 52 patients with thyroid-associated ophthalmopathy who completed intravenous glucocorticoid (IVGC) therapy with standardized vitamin D and calcium supplementation at the First Affiliated Hospital of Xi'an Jiaotong University. The study assessed treatment response to IVGC alongside baseline biomarkers including triglycerides, thyroxine, duration of ophthalmopathy, beta-CTX, N-MID OC, and 25(OH)D levels.

Analysis revealed that baseline triglycerides and thyroxine levels were significantly higher in non-responders compared to responders. Additionally, the duration of ophthalmopathy was longer in non-responders. Conversely, baseline beta-CTX and N-MID OC levels were higher in responders. Baseline 25(OH)D deficiency was present in 73.08% of the patients.

Safety and tolerability data were not reported, as were discontinuations and serious adverse events. The study notes that the relationship between vitamin D and IVGC efficacy remains undefined. Because this is an observational study, causal inferences cannot be made regarding the impact of vitamin D supplementation or baseline biomarkers on treatment outcomes.

Imagine waking up with puffy eyes and double vision. It is scary when your thyroid acts up. You want to know if the treatment will actually help.

Why Doctors Care Now

Thyroid eye disease makes eyes look swollen and painful. Doctors often use strong steroids to fix it. But some people do not get better.

Many patients feel frustrated when the medicine does not work. They worry about side effects from long-term use. Finding a way to predict success is vital.

This condition affects the muscles and fat behind the eyes. It can lead to vision loss if ignored. Current treatments are powerful but hit or miss.

The Unexpected Connection

Doctors used to guess which patients would respond. They gave the same treatment to everyone. But here is the twist.

A new study suggests a simple blood test might help. It looks at vitamin D levels before starting therapy. This changes how we approach the problem.

We used to believe steroids worked the same for all. Now we see a link to nutrition and health. The body needs specific nutrients to heal.

Think of your body like a car engine. Steroids are the fuel to stop inflammation. Vitamin D helps the engine run smoothly.

Without enough fuel, the car stalls. Similarly, low vitamin D might block the treatment. The immune system needs balance to heal properly.

This nutrient helps regulate how your body fights inflammation. It acts like a switch for your defense system. Without it, the medicine may not turn on.

Researchers looked at 52 patients from a hospital in China. They checked blood levels before and after treatment. They wanted to see what made the difference.

Most patients had low vitamin D at the start. About 73 percent were deficient in the nutrient. This was true for both groups.

They tracked bone health markers in the blood. These markers show how active the bones are. Responders had higher levels before treatment began.

Those who got better had different bone markers in their blood. These markers show how active the bones are. Responders had higher levels before treatment began.

Non-responders had higher triglycerides and longer disease duration. This suggests overall health matters too. It is not just about the eye.

This doesn’t mean this treatment is available yet.

Experts say this is a helpful clue for future care. It points to a simple blood test. It could save time and money for patients.

You should not start taking extra vitamins on your own. Ask your doctor about your levels. They can check if you are low.

Self-medicating can cause other health problems. Always follow the advice of your medical team. They know your full history.

The Catch to Know

The group was small for a major study. The study looked at past records. This limits how sure we can be.

The study was done in one hospital. Results might differ in other countries. We need more data to be sure.

More research is needed to confirm these results. Doctors will wait for larger studies. Approval takes time to ensure safety.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundIntravenous glucocorticoids (IVGC) represent first-line therapy for active moderate-to-severe thyroid-associated ophthalmopathy (TAO). The relationship between vitamin D (VitD) and IVGC efficacy in TAO remains undefined.MethodsThis retrospective study grouped TAO patients completing IVGC therapy with standardized VitD/calcium supplementation at First Affiliated Hospital of Xi’an Jiaotong University (2015–2019). Serum 25-hydroxyvitamin D (25(OH)D) and bone markers were measured pre/post-treatment. Multivariate regression and ROC analysis identified predictors.ResultsIn total, 52 TAO patients were enrolled, including 33 responders and 19 non-responders. Non-responders had significantly higher baseline triglycerides, thyroxine and longer duration of ophthalmopathy. Responders exhibited higher baseline β-CTX and N-MID OC. Notably, 73.08% of patients had baseline 25(OH)D deficiency (
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.